# Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

> **NCT06481241** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 77 (estimated)

## Conditions studied

- Philadelphia Chromosome Negative ALL
- Acute Lymphoblastic Leukemia, Adult

## Interventions

- **COMBINATION_PRODUCT:** CAR-T cells
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06481241
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481241, "Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06481241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*